Mayne Pharma Group Limited
Mayne Pharma Group Limited Fundamental Analysis
Mayne Pharma Group Limited (MAYNF) shows moderate financial fundamentals with a PE ratio of -2.34, profit margin of -20.45%, and ROE of -23.03%. The company generates $0.4B in annual revenue with moderate year-over-year growth of 5.14%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -7.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze MAYNF's fundamental strength across five key dimensions:
Efficiency Score
WeakMAYNF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentMAYNF trades at attractive valuation levels.
Growth Score
ExcellentMAYNF delivers strong and consistent growth momentum.
Financial Health Score
ExcellentMAYNF maintains a strong and stable balance sheet.
Profitability Score
WeakMAYNF struggles to sustain strong margins.
Key Financial Metrics
Is MAYNF Expensive or Cheap?
P/E Ratio
MAYNF trades at -2.34 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, MAYNF's PEG of -0.26 indicates potential undervaluation.
Price to Book
The market values Mayne Pharma Group Limited at 0.55 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 9.29 times EBITDA. This is generally considered low.
How Well Does MAYNF Make Money?
Net Profit Margin
For every $100 in sales, Mayne Pharma Group Limited keeps $-20.45 as profit after all expenses.
Operating Margin
Core operations generate -11.15 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-23.03 in profit for every $100 of shareholder equity.
ROA
Mayne Pharma Group Limited generates $-8.85 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Mayne Pharma Group Limited generates limited operating cash flow of $22.44M, signaling weaker underlying cash strength.
Free Cash Flow
Mayne Pharma Group Limited produces free cash flow of $15.72M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.19 in free cash annually.
FCF Yield
MAYNF converts 8.08% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-2.34
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.26
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.55
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.48
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.13
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.33
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.23
vs 25 benchmark
ROA
Return on assets percentage
-0.09
vs 25 benchmark
ROCE
Return on capital employed
-0.07
vs 25 benchmark
How MAYNF Stacks Against Its Sector Peers
| Metric | MAYNF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -2.34 | 28.45 | Better (Cheaper) |
| ROE | -23.03% | 763.00% | Weak |
| Net Margin | -20.45% | -45265.00% (disorted) | Weak |
| Debt/Equity | 0.13 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 1.33 | 2795.60 | Neutral |
| ROA | -8.85% | -16588.00% (disorted) | Weak |
MAYNF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Mayne Pharma Group Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-11.86%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
0.18%
Industry Style: Defensive, Growth, Innovation
GrowingFCF CAGR
-82.72%
Industry Style: Defensive, Growth, Innovation
Declining